| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
IRulya Therapeutics Inc.
13G
IRLA · 22053A305
|
6.0% |
10/14/2026
Event 10/6/2026
|
|||
| Foresite Capital Fund VI LP | 4.5% | ||||
| Foresite Capital Management VI, LLC | 4.5% | ||||
| Foresite Public & Crossover Opportunities Fund I, L.P. | 1.5% | ||||
| Foresite Public & Crossover Opportunities Management I, LLC | 1.5% | ||||
| James B. Tananbaum | 6.0% | ||||
|
Latigo Biotherapeutics, Inc.
13D
LTGO · 517954103
|
14.5% |
8/17/2026
Event 8/10/2026
|
|||
| Foresite Capital Fund VI LP | 3.5% | ||||
| Foresite Capital Management VI, LLC | 3.5% | ||||
| Foresite Capital Fund V, L.P. | 5.6% | ||||
| Foresite Capital Management V, LLC | 5.6% | ||||
| Foresite Capital Opportunity Fund V, L.P. | 5.4% | ||||
| Foresite Capital Opportunity Management V, LLC | 5.4% | ||||
| James B. Tananbaum | 14.5% | ||||
|
Latigo Biotherapeutics, Inc.
13D
LTGO · 517954103
|
14.5% |
8/17/2026
Event 8/10/2026
|
|||
| Foresite Capital Fund VI LP | 3.5% | ||||
| Foresite Capital Management VI, LLC | 3.5% | ||||
| Foresite Capital Fund V, L.P. | 5.6% | ||||
| Foresite Capital Management V, LLC | 5.6% | ||||
| Foresite Capital Opportunity Fund V, L.P. | 5.4% | ||||
| Foresite Capital Opportunity Management V, LLC | 5.4% | ||||
| James B. Tananbaum | 14.5% | ||||
|
Verastem, Inc.
13G/A
Amendment 1
VSTM · 92337C203
|
3.6% |
5/15/2026
Event 3/31/2026
|
|||
| Foresite Capital Fund VI LP | 3.6% | ||||
| Foresite Capital Management VI LLC | 3.6% | ||||
| Tananbaum James B. | 3.6% | ||||
|
Alumis Inc.
13D/A
Amendment 4
ALMS · 022307102
|
12.7% |
4/3/2026
Event 4/1/2026
|
|||
| Foresite Capital Fund VI LP | 3.4% | ||||
| Foresite Capital Management VI, LLC | 3.4% | ||||
| Foresite Capital Fund V, L.P. | 4.6% | ||||
| Labs Co-Invest V, LLC | 0.2% | ||||
| Foresite Capital Management V, LLC | 4.8% | ||||
| Foresite Capital Opportunity Fund V, L.P. | 2.4% | ||||
| Foresite Capital Opportunity Management V, LLC | 2.4% | ||||
| Foresite Labs Fund I, L.P. | 1.6% | ||||
| Foresite Labs Management I, LLC | 1.6% | ||||
| Foresite Labs Affiliates 2021, LLC | 0% | ||||
| Foresite Labs, LLC | 0% | ||||
| James B. Tananbaum | 12.7% | ||||
|
CASI Pharmaceuticals, Inc.
13G/A
Amendment 3
CASIF · G1933S101
|
0% |
2/13/2026
Event 12/31/2025
|
|||
| Foresite Capital Fund VI LP | 0% | ||||
| Foresite Capital Management VI LLC | 0% | ||||
| James Tananbaum | 0% | ||||
|
Alumis Inc.
13D/A
Amendment 3
ALMS · 022307102
|
14.1% |
1/12/2026
Event 1/8/2026
|
|||
| Foresite Capital Fund VI LP | 3.7% | ||||
| Foresite Capital Management VI, LLC | 3.7% | ||||
| Foresite Capital Fund V, L.P. | 5.0% | ||||
| Labs Co-Invest V, LLC | 0.2% | ||||
| Foresite Capital Management V, LLC | 5.1% | ||||
| Foresite Capital Opportunity Fund V, L.P. | 2.5% | ||||
| Foresite Capital Opportunity Management V, LLC | 2.5% | ||||
| Foresite Labs Fund I, L.P. | 1.7% | ||||
| Foresite Labs Management I, LLC | 1.7% | ||||
| Foresite Labs Affiliates 2021, LLC | 1.0% | ||||
| Foresite Labs, LLC | 1.0% | ||||
| James B. Tananbaum | 14.1% | ||||
|
CASI Pharmaceuticals, Inc.
13G/A
Amendment 2
CASIF · G1933S101
|
6.3% |
11/14/2025
Event 9/30/2025
|
|||
| Foresite Capital Fund VI LP | 6.3% | ||||
| Foresite Capital Management VI LLC | 6.3% | ||||
| James Tananbaum | 6.3% | ||||
|
Verastem, Inc.
13G
VSTM · 92337C203
|
5.1% |
10/23/2025
Event 10/16/2025
|
|||
| Foresite Capital Fund VI LP | 5.1% | ||||
| Foresite Capital Management VI, LLC | 5.1% | ||||
| Tananbaum James B. | 5.1% | ||||
|
CASI Pharmaceuticals, Inc.
13G/A
Amendment 1
CASIF · G1933S101
|
5.1% |
8/12/2025
Event 6/30/2025
|
|||
| Foresite Capital Fund VI, L.P. | 5.1% | ||||
| Foresite Capital Management VI, LLC | 5.1% | ||||
| James Tananbaum | 5.1% | ||||
|
Alumis Inc.
13D/A
Amendment 2
ALMS · 022307102
|
15.9% |
6/10/2025
Event 5/21/2025
|
|||
| Foresite Capital Fund VI, L.P. | 4.4% | ||||
| Foresite Capital Management VI, LLC | 4.4% | ||||
| Foresite Capital Fund V, L.P. | 5.8% | ||||
| Labs Co-Invest V, LLC | 0.2% | ||||
| Foresite Capital Management V, LLC | 6.0% | ||||
| Foresite Capital Opportunity Fund V, L.P. | 2.1% | ||||
| Foresite Capital Opportunity Management V, LLC | 2.1% | ||||
| Foresite Labs Fund I, L.P. | 2.0% | ||||
| Foresite Labs Management I, LLC | 2.0% | ||||
| Foresite Labs Affiliates 2021, LLC | 1.2% | ||||
| Foresite Labs, LLC | 1.2% | ||||
| James B. Tananbaum | 15.9% | ||||
|
Alumis Inc.
13D/A
Amendment 1
ALMS · 022307102
|
32.2% |
5/7/2025
Event 8/13/2024
|
|||
| Foresite Capital Fund VI, L.P. | 9.0% | ||||
| Foresite Capital Management VI, LLC | 9.0% | ||||
| Foresite Capital Fund V, L.P. | 11.8% | ||||
| Labs Co-Invest V, LLC | 0.4% | ||||
| Foresite Capital Management V, LLC | 12.2% | ||||
| Foresite Capital Opportunity Fund V, L.P. | 4.3% | ||||
| Foresite Capital Opportunity Management V, LLC | 4.3% | ||||
| Foresite Labs Fund I, L.P. | 4.2% | ||||
| Foresite Labs Management I, LLC | 4.2% | ||||
| Foresite Labs Affiliates 2021, LLC | 2.5% | ||||
| Foresite Labs, LLC | 2.5% | ||||
| James B. Tananbaum | 32.2% | ||||
|
enGene Holdings, Inc.
13G/A
Amendment 1
ENGN · 29286M105
|
0% |
2/14/2025
Event 9/30/2024
|
|||
| Foresite Capital Fund VI, L.P. | 0% | ||||
| Foresite Capital Management VI, LLC | 0% | ||||
| James Tananbaum | 0% | ||||
|
RAPT Therapeutics, Inc.
13G
RAPT · 75382E109
|
9.3% |
12/30/2024
Event 12/23/2024
|
|||
| Foresite Capital Fund VI, L.P. | 9.3% | ||||
| Foresite Capital Management VI, LLC | 9.3% | ||||
| James Tananbaum | 9.3% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.